A Multicenter, Randomized, Double-Blind, Double-Dummy, Active Controlled Clinical Trial for the Validation of Optimum Dose and Preliminary Evaluation of Efficacy and Safety of Evogliptin in Patients With Type 2 Diabetes Mellitus
Phase of Trial: Phase II
Latest Information Update: 26 Sep 2017
At a glance
- Drugs Evogliptin (Primary) ; Sitagliptin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms EVOLUTION
- Sponsors Eurofarma
- 14 Sep 2017 Status changed from not yet recruiting to recruiting.
- 10 Jun 2017 Biomarkers information updated
- 06 Dec 2016 Planned initiation date changed from 1 Feb 2017 to 1 Mar 2017.